THE EFFECTIVENESS OF INFLIXIMAB IN CHILDREN WITH IBD, DEPENDING ON THE LEVEL OF CIRCULATING CYTOKINES AND THE CONCENTRATION OF THE DRUG


如何引用文章

全文:

详细

In this study, we assessed the blood circulating proinflammatory and inflammatory cytokines and obtained the cut-off level for TNF, IL-22, IL-23, IL-27 between groups of children in exacerbation and remission during treatment with infliximab. There was a significant decrease in serum IFN in children in exacerbation compared with the group of children in remission for both UC and CD. It was found that the younger the age of the child, the faster the antibodies to infliximab were formed. The level of TNFin the blood, the residual level of infl iximab, as well as the level of antibodies to infliximab can serve as predictors of non-response and loss of effect from therapy with TNF blockers.

作者简介

T. Radygina

National Medical Research Center for Children’s Health

编辑信件的主要联系方式.
Email: Radygina.TV@nczd.ru

Ph.D. (Medicine), Senior Research Associate, Laboratory of Experimental Immunology and Virology, 

Moscow

俄罗斯联邦

A. Illarionov

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

PhD student of the Gastroenterological department with hepatological group,

Moscow

俄罗斯联邦

D. Gerasimova

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

intern oftheLaboratory of Experimental Immunology and Virology,

Moscow

俄罗斯联邦

A. Anushenko

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

pediatrician of the Gastroenterological department with hepatological group,

Moscow

俄罗斯联邦

Y. Komakh

The S. Fyodorov Eye Microsurgery Federal State Institution

Email: fake@neicon.ru

PhD, Head of the Transplantology and Cellular Biology Laboratory,

Moscow

俄罗斯联邦

A. Potapov

National Medical Research Center for Children’s Health

Email: fake@neicon.ru
Moscow 俄罗斯联邦

S. Petrichuk

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

PhD, MD (Biology), Professor, Main Research Associate, Laboratory of Experimental Immunology and Virology,

Moscow

俄罗斯联邦

A. Fisenko

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

Head of the National Medical Research Center for Children’s Health,

Moscow

俄罗斯联邦

参考

  1. Ungar B., Levy I., Yavne Y., Yavzori M., Picard O., Fudim E., Loebstein R., Chowers Y., Eliakim R., Kopylov U., Ben-Horin S. Optimizing Anti-TNF-α Therapy: Serum Levels ofInfliximab and Adalimumab Are Associated With Mucosal Healing in Patients WithInflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2016;14:550–7.
  2. Hanauer S. B., Wagner C. L., Bala M., Mayer L., Travers S., Diamond R. H., Olson A., Bao W., Rutgeerts P. Incidence and importance of antibody responsesto infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:542–53. treatment in Crohn’s disease.

版权所有 © Radygina T.V., Illarionov A.S., Gerasimova D.G., Anushenko A.O., Komakh Y.A., Potapov A.S., Petrichuk S.V., Fisenko A.P., 2019

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可
##common.cookie##